Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, van Raalte DH

European journal of endocrinology24 Oct 2016Cited by 47 (Europe PMC)

PMID27777261DOI10.1530/eje-16-0507PepBankPUB-27777261

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, 12-week liraglutide treatment increased resting heart rate by 6.6 BPM.
In plain wordsIn adults with type 2 diabetes, 12 weeks of liraglutide raised resting heart rate compared with placebo.
Peptide
Liraglutide
Outcome
IncreaseResting heart rate change
Study
n = 36
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Resting heart rate change
6.6 BPM
liraglutide 12 weeks
Source sentences
Summary
Twelve-week treatment with liraglutide increased RHR (+6.6 ± 2.1 BPM
1 context sentence(design, population, supporting numbers)
Summary · context
Subsequently, patients were again randomised to receive the GLP-1 receptor agonist liraglutide (n = 19) or matching placebo (n = 17) for 12 weeks.
Report a problemFND-2777726101
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, 12-week liraglutide treatment reduced systolic blood pressure by 12.6 mmHg.
In plain wordsIn adults with type 2 diabetes, 12 weeks of liraglutide lowered systolic blood pressure compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure change
Study
n = 36
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Systolic blood pressure change
−12.6 mmHg
liraglutide 12 weeks
Source sentences
Summary
while reducing systolic BP (-12.6 ± 4.7 mmHg
1 context sentence(design, population, supporting numbers)
Summary · context
Subsequently, patients were again randomised to receive the GLP-1 receptor agonist liraglutide (n = 19) or matching placebo (n = 17) for 12 weeks.
Report a problemFND-2777726102
03HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, 12-week liraglutide treatment reduced stroke volume.
In plain wordsIn adults with type 2 diabetes, 12 weeks of liraglutide reduced the amount of blood pumped per heartbeat compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseStroke volume
Study
n = 36
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
and stroke volume (all P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Subsequently, patients were again randomised to receive the GLP-1 receptor agonist liraglutide (n = 19) or matching placebo (n = 17) for 12 weeks.
Report a problemFND-2777726103
04HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, cardiac output remained unchanged with 12-week liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, 12 weeks of liraglutide did not change cardiac output.
Peptide
Liraglutide
Outcome
No significant changeCardiac output
Study
n = 36
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Cardiac output, vascular resistance, arterial stiffness and SNS activity remained unchanged (all P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Subsequently, patients were again randomised to receive the GLP-1 receptor agonist liraglutide (n = 19) or matching placebo (n = 17) for 12 weeks.
Report a problemFND-2777726104
05HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, vascular resistance remained unchanged with 12-week liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, 12 weeks of liraglutide did not change vascular resistance.
Peptide
Liraglutide
Outcome
No significant changeVascular resistance
Study
n = 36
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Cardiac output, vascular resistance, arterial stiffness and SNS activity remained unchanged (all P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Subsequently, patients were again randomised to receive the GLP-1 receptor agonist liraglutide (n = 19) or matching placebo (n = 17) for 12 weeks.
Report a problemFND-2777726105
06HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, arterial stiffness remained unchanged with 12-week liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, 12 weeks of liraglutide did not change arterial stiffness.
Peptide
Liraglutide
Outcome
No significant changeArterial stiffness
Study
n = 36
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Cardiac output, vascular resistance, arterial stiffness and SNS activity remained unchanged (all P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Subsequently, patients were again randomised to receive the GLP-1 receptor agonist liraglutide (n = 19) or matching placebo (n = 17) for 12 weeks.
Report a problemFND-2777726106
07HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, sympathetic nervous system activity remained unchanged with 12-week liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, 12 weeks of liraglutide did not change sympathetic nervous system activity.
Peptide
Liraglutide
Outcome
No significant changeSympathetic nervous system activity
Study
n = 36
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Cardiac output, vascular resistance, arterial stiffness and SNS activity remained unchanged (all P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Subsequently, patients were again randomised to receive the GLP-1 receptor agonist liraglutide (n = 19) or matching placebo (n = 17) for 12 weeks.
Report a problemFND-2777726107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.